Lexicon Genetics Renews and Expands Licenses for Gene Targeting Technology To Biogen, Inc.
Thursday October 24, 7:01 am ET
THE WOODLANDS, Texas, Oct. 24 /PRNewswire-FirstCall/ -- Lexicon Genetics Incorporated (Nasdaq: LEXG - News) has issued a non-exclusive license to Biogen, Inc. (Nasdaq: BGEN - News) for the use of Lexicon's patented gene targeting technologies in Biogen's internal research programs. Financial terms of the multi-year agreement were not disclosed.
In the agreement announced today, Biogen renewed its license to use Lexicon's positive negative selection technology and received non-exclusive rights under the patent covering Lexicon's isogenic DNA gene targeting technology.
"We are pleased that Biogen has taken an additional license to our patented gene targeting technologies," said Dr. Arthur T. Sands, Lexicon president and chief executive officer. "We believe the increased interest in our technology reflects the growing value that is associated with in vivo target validation," he said.
About Lexicon Genetics
Lexicon Genetics Incorporated is a biopharmaceutical company focused on the discovery of breakthrough treatments for human disease. Lexicon is using gene knockout technology to systematically discover the physiological functions and medical uses of genes. The Company's gene function discoveries fuel therapeutic discovery programs in cardiovascular disease, diabetes, obesity, immune disorders, neurological disease and cancer. Lexicon has established drug discovery alliances and functional genomics collaborations with leading pharmaceutical and biotechnology companies, research institutes and academic institutions throughout the world to commercialize its technology and further develop its discoveries.
Additional information about the Company is available through Lexicon's corporate website, www.lexicon-genetics.com . |
